Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective, epithelial, and neural tissues. It functions primarily as a viscoelastic lubricant in synovial fluid and as a structural component in the extracellular matrix. Therapeutic forms include intra-articular injections (viscosupplementation) and topical agents for wound healing or dermatologic use.
## Primary Indications
* **Intra-articular (IA):** Osteoarthritis of the knee in patients who have failed conservative non-pharmacologic therapy or simple analgesics.
* **Topical/Ocular:** Wound dressings, surgical adhesives, and dry eye syndrome (as artificial tears).
## Adult Dosing
* **Intra-articular (Knee OA):** Dosing depends heavily on the specific formulation (e.g., Hyalgan, Synvisc, Euflexxa).
* *Hyalgan:* 20 mg (2 mL) weekly for 5 weeks.
* *Synvisc-One:* 48 mg (6 mL) once, single injection.
* *Euflexxa:* 20 mg (2 mL) weekly for 3 weeks.
* **Topical/Ophthalmic:** Apply as needed per product labeling.
## Pediatric Dosing
Safety and efficacy have not been established for IA use in pediatric patients. Use in children is generally limited to specific dermatologic or ophthalmic applications per manufacturer guidelines. Dosing is not standardized.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No standard dose adjustments exist; HA is localized to the injection site or surface and systemic absorption is minimal.
* **Elderly:** No routine dose adjustments required.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Known hypersensitivity to avian proteins (if using avian-derived products, e.g., Hyalgan).
* Active joint infection, skin disease, or infection in the area of the injection site.
* Severe inflammation of the knee joint.
## Adverse Effects
* **Common:** Arthralgia, injection site pain, joint swelling/effusion, pruritus.
* **Serious:** Pseudogout (acute crystalline arthritis), severe local inflammatory reaction (flare), systemic anaphylaxis (rare).
## Key Drug Interactions
* **Disinfectants:** Do not concurrently use skin disinfectants containing quaternary ammonium salts (e.g., benzalkonium chloride) for skin preparation, as HA can precipitate in their presence.
## Monitoring
* **Efficacy:** Assessment of joint pain, stiffness, and physical function; peak effect often delayed until 4–12 weeks post-injection.
* **Safety:** Monitor for signs of acute joint inflammation (warmth, increased effusions) within 24–48 hours of injection.
## Clinical Pearls
* **Viscosupplementation:** HA does not "repair" cartilage but provides symptomatic relief through lubrication and shock absorption.
* **Technique:** Sterile technique is paramount for IA injections to prevent septic arthritis.
* **Formulation Variability:** Different HA brands have vastly different molecular weights and cross-linking properties, affecting injection frequency and duration of effect. Always confirm the specific product label.
* **Systemic Absorption:** Systemic absorption following intra-articular administration is negligible.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the most current product monograph or institutional clinical protocols before prescribing or administering medication.
